Distinguished in Clear Cell Sarcoma

Dr. Edward M. Uchio

Urology
Uci Department Of Urology
101 The City Dr S, 
Orange, CA 
Offers Telehealth
Distinguished in Clear Cell Sarcoma
Uci Department Of Urology
101 The City Dr S, 
Orange, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Edward Uchio is an Urologist in Orange, California. Dr. Uchio is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Bladder Cancer, Prostate Cancer, Non-Muscle Invasive Bladder Cancer, Aquablation, and Prostatic Artery Embolization.

His clinical research consists of co-authoring 64 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Urology in CT
Hospital Affiliations
University Of California Irvine Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

UCI DEPARTMENT OF UROLOGY
101 The City Dr S, Orange, CA 92868

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, AB680, Enzalutamide, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2025
Intervention Type: Other, Biological
Study Drugs: CG0070, N-Dodecyl-B-D-Maltoside
Study Phase: Phase 3
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Enrollment Status: Completed
Publish Date: September 25, 2024
Intervention Type: Biological, Other
Study Drugs: Engineered Oncolytic Adenovirus, Pembrolizumab, N-Dodecyl-B-D-Maltoside
Study Phase: Phase 2
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
A Prospective Post Market Study of Patients With Symptomatic Benign Prostatic Hyperplasia Treated by Prostatic Artery Embolization With Embosphere® Microspheres
A Prospective Post Market Study of Patients With Symptomatic Benign Prostatic Hyperplasia Treated by Prostatic Artery Embolization With Embosphere® Microspheres
Enrollment Status: Completed
Publish Date: December 18, 2023
Intervention Type: Device
Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Biological, Other
Study Drug: Rilimogene galvacirepvec
Study Phase: Phase 2
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Enrollment Status: Terminated
Publish Date: June 23, 2022
Intervention Type: Diagnostic test
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Enrollment Status: Terminated
Publish Date: November 11, 2021
Intervention Type: Device, Procedure
Study Phase: Not Applicable
View 8 Less Clinical Trials

64 Total Publications

The Establishment of Prostate-specific, SKP2 Humanized Mice by CRISPR Knock-in Method Reveals Neoplastic Initiation and Microenvironmental Reprogramming.
The Establishment of Prostate-specific, SKP2 Humanized Mice by CRISPR Knock-in Method Reveals Neoplastic Initiation and Microenvironmental Reprogramming.
Journal: bioRxiv : the preprint server for biology
Published: July 14, 2025
Similar Doctors
Distinguished in Clear Cell Sarcoma
Dr. Jaime Landman
Urology
Distinguished in Clear Cell Sarcoma
Dr. Jaime Landman
Urology

Uci Department Of Urology

101 The City Dr S, 
Orange, CA 
 (0.1 miles away)
714-456-6054
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jaime Landman is an Urologist in Orange, California. Dr. Landman is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Ureterocele, WT1-Related Wilms Tumor Syndromes, Renal Cell Carcinoma (RCC), Reconstructive Urology Surgery, and Nephrectomy.

Distinguished in Clear Cell Sarcoma
Dr. Hooman Djaladat
Urology
Distinguished in Clear Cell Sarcoma
Dr. Hooman Djaladat
Urology

USC Care Medical Group Inc

1500 San Pablo St, 
Los Angeles, CA 
 (26.0 miles away)
323-442-8444
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hooman Djaladat is an Urologist in Los Angeles, California. Dr. Djaladat is rated as an Elite provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy.

Distinguished in Clear Cell Sarcoma
Dr. Clayton S. Lau
Urology
Distinguished in Clear Cell Sarcoma
Dr. Clayton S. Lau
Urology

City Of Hope Medical Foundation

209 Fair Oaks Ave, 
South Pasadena, CA 
 (27.6 miles away)
626-396-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Clayton Lau is an Urologist in South Pasadena, California. Dr. Lau is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Bladder Cancer, Nephrectomy, and Cystectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Uchio's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 10 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile